Kornimate/medical-research-clean huggingface dataset:
clinic-based nasopharyngoesophagogastroscopy following bariatric surgery

Conditions: Obesity

Summary: this study aims to determine that this new technology, nasopharyngoendoscopy, is just as effective in diagnosing problems as the current gold standard.

obesity is a public health problem. currently, the best treatment is surgery. however, 15% of patients after surgery have problems such as nausea, pain, vomiting, heartburn or regurgitation. to investigate these problems, an endoscopy is used. yet, endoscopy has some disadvantages such as the need for intravenous sedation, need to take time off work, need for special endoscopy units and nurses and a delay in diagnosing because the endoscopy cannot be done at the time of the clinic visit. a new technology called clinic-based nasopharyngoendoscopy can potentially solve many of the problems with the current endoscopy. this study aims to determine that this new technology is just as effective in diagnosing problems as the current gold standard.

Eligibility criteria:
inclusion criteria: * post-operative gastric bypass patients at st. joseph's healthcare hamilton * no previous nasal or pharyngeal surgery * foregut dyspeptic symptoms including: nausea, vomiting, regurgitation, epigastric pain, reflux and/or hematemesis * require endoscopy for investigation of foregut symptoms * able to provide consent exclusion criteria: * patients who have not undergone gastric bypass surgery * inability to give consent

Keywords: obesity endoscopy nasopharyngoesophagogastroscopy bariatric surgery gastric bypass surgery
a multicenter study to evaluate the efficacy and safety of pep005 (ingenol mebutate) gel when used to treat actinic keratoses (aks) on the non head locations

Conditions: Actinic Keratoses

Summary: the purpose of this study is to determine whether topical application of pep005 is effective for the treatment of actinic keratoses.


Eligibility criteria:
inclusion criteria: * must be male or female and at least 18 years of age. * female patients must be of: * non-childbearing potential; * childbearing potential, provided negative serum and urine pregnancy test and using effective contraception. * 4 to 8 ak lesions on non-head locations. exclusion criteria: * cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area. * treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks. * treatment with 5-fu, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area

Keywords: peplin actinic keratosis pep005
intranasal fentanyl for initial treatment of a vaso-occlusive crisis

Conditions: Anemia, Sickle Cell; Pain

Summary: the purpose of this study is to determine if intranasal fentanyl can decrease the pain of patients with sickle cell disease who present to the pediatric emergency department with a vaso-occlusive crisis.

principles of therapy for treatment of vaso-occlusive crises include early aggressive analgesic therapy with opiates and non-steroidal anti-inflammatory agents as well as fluid administration. it is known that there is a significant delay in time to administration of analgesics in children with voc in the ed. the most easily modifiable factor that contributes to delayed opiate administration is route of administration. intranasal medication administration is an easy, rapid way to administer opiates with minimal discomfort as well as bypassing first past metabolism and the blood brain barrier. intranasal fentanyl has been shown to be a safe and effective analgesic for treatment of acute pain in children, reaching therapeutic effect in 2-10 minutes after administration. the investigators believe that intranasal fentanyl therapy will be able to provide expedited and effective pain therapy to patients with sickle cell disease presenting to the pediatric emergency department with a vaso-occlusive crisis

Eligibility criteria:
inclusion criteria: * sickle cell disease * ages 3 years - 21 years exclusion criteria for enrollment: * pregnancy * known allergy to fentanyl * usage of daily home opiates exclusion criteria at presentation in ed with a painful crisis: * wong baker faces pain score \<6 * systolic blood pressure \< 5 percentile for age * oxygen saturation \<92% on room air * temperature \> 102°f * respiratory distress * priapism * isolated abdominal pain * isolated headache * new neurological symptoms * severe rhinorrhea or epistaxis * history of trauma * pregnancy

Keywords: fentanyl intranasal sickle cell vasoocclusive crisis pain crisis pediatrics
detection and enumeration of circulating tumor cells in rectal cancer

Conditions: Rectal Cancer

Summary: rectal cancer is one of the most common malignant tumors in the world. however, there's also no reliable and sensitive method to monitor diseases and evaluate therapy responses till now. circulating tumor cells, which could reflect tumor's status correctly and reliably, may be a promising method in this field. this study is to investigate the role of circulating tumor cells in evaluating and predicting the responses of chemoradiotherapy in rectal cancer.


Eligibility criteria:
inclusion criteria: * histologically verified rectal carcinoma * locally advanced tumor (ct3-4 and/or n+ by transrectal ultrasound and/or pelvic magnetic resonance imaging) * the distance from anal verge \<= 12cm * with or without metastasis * age 18-75 years old * ecog ps 0-2 * no previous chemotherapy or radiotherapy for rectal carcinoma * written informed consent exclusion criteria: * no histologically verified rectal carcinoma * rectal cancer with stage i * distance from verge \>12cm * age \ =75 years old * performed previously chemotherapy or radiotherapy * infection diseases within three months * serious other diseases * no written informed consent

Keywords: rectal cancer circulating tumor cells predict responses
a chart review of newborns with the presence of confirmed or suspected maternal chorioamnionitis and utilization of the early onset sepsis calculator

Conditions: Maternal; Chorioamnionitis, Affecting Fetus; Early-Onset Sepses, Neonatal

Summary: this study will review practices in relation to chorioamnionitis (cam) before and after to the implementation of the neonatal early-onset sepsis (eos) risk calculator to determine the effect in the nursery at banner - university medical center phoenix. newborns enrolled will be at least 35 weeks gestational age (ga) and have a maternal diagnosis of at least suspected or confirmed cam. the data will include those newborns whose assessment and treatment were not guided by the eos calculator which was implemented on august 28, 2019 and those with which the eos calculator was utilized. a secondary objective is to show the economic impact with utilization of the eos calculator. data collected will include full laboratory workups including complete blood counts (cbc), blood cultures, antibiotic usage, length of time in the newborn nursery and total length of stay.


Eligibility criteria:
inclusion criteria: * asymptomatic newborns 35 weeks or greater ga born at banner - university medical center phoenix whose mothers were determined or suspected to have cam. exclusion criteria: * direct nicu admissions * subjects may be excluded at investigator discretion
reassessment of premedication in surgery

Conditions: Anxiety

Summary: the purpose of this study is to test the level of anxiety in patients, the day before surgery (late afternoon) and immediately prior to surgery in 3 parallel groups of patients. * one receiving placebo before going to sleep (before sleep), the day prior surgery and placebo when awakening (awakening), the day of surgery * one receiving zopiclone (7.5 mg) before sleep and placebo at awakening * one receiving placebo before sleep and alprazolam (0.5 mg)at awakening double blind, randomized controlled study

eligibility: * 18 to 65 years old * elective surgery * in-hospital preoperative night outcome measures: * anxiety scales * demographic data

Eligibility criteria:
inclusion criteria: * age 18-65 years old * elective surgery * in-hospital night before surgery exclusion criteria: * myasthenia gravis * chronic intake of psychotropic drugs * opiates intake * severe obstructive sleep apnea * intracranial hypertension * morbid obesity * myasthenia gravis * acute severe medical disorder * non health insurance coverage * protected patients by law * pregnancy * non french speaking

Keywords: premedication benzodiazepine anti-anxiety agents anxiety surgery adult human
second line oxaliplatin based chemotherapy alone versus oxaliplatin based pipac and chemotherapy in colorectal peritoneal carcinomatosis : a phase ii randomize mutli-centric study

Conditions: Peritoneal Carcinomatosis

Summary: colorectal cancer is the third most common cancer in men and second in women. it represent 345'346 new cases per year in europe and 134'349 in the united states of america. the peritoneal cavity is the second most frequent site, after liver, for colorectal cancer relapse.peritoneal carcinomatosis (pc) is found in approximately 5 % of patients diagnosed with colorectal cancer and 24% of patients with synchronous metastasis at the time of diagnosis. eight percent of colorectal cancer patient will develop pc during the course of their disease . currently systemic chemotherapy is the standard of care for the treatment of unresectable peritoneal carcinomatosis from colorectal cancer with a median survival rate of 16.3 months peritoneal carcinomatosis has a poor response to systemic chemotherapy due to a weak penetration of agents into the peritoneum. a new approach of intraperitoneal carcinomatosis is now developed: pressurized intraperitoneal aerosol chemotherapy (pipac) is used to deliver intraperitoneal chemotherapy. it enhances the effect of chemotherapy because of the physical properties of aerosol and pressure. pipac is a safe with a 23% morbidity and tolerated technic that is now well described. we want to conduct a study to prove or infirm the superiority of pipac associated with systemic chemotherapy compare to systemic chemotherapy alone in peritoneal carcinomatosis from colorectal cancer


Eligibility criteria:
inclusion criteria: * patients 18 \< age ≤ 75 years old with performance status (who) ≤ 2 histologically evidenced synchronous or metachronous pm of a colorectal cancer with a pci ≥ 15 (no complete resectable pc) histologically evidenced synchronous or metachronous pm of a colorectal cancer with a pci \< 15 + liver or pulmonary unresectable metastases pci \< 15 but with progression at the restaging after the first line of chemotherapy unresectable peritoneal relapse secondary to cytoreduction surgery exclusion criteria: * patients with clinically significant ascites (\> 3000 cc) * pleural effusion requiring evacuation for respiratory failure * small bowel occlusion with no possible food intake * presence of comorbidities, notably serious chronic diseases or organ failure
optimal suture choice for improved scar outcomes

Conditions: Cicatrix

Summary: certain parts of the body, such as the chest, back, and shoulders, are notorious for producing cosmetically poor scars after cutaneous surgery. while very little research has been done to understand these poor outcomes, it is generally thought that increased tension across the skin inherent to these body areas leads to significant widening of the final scar. historically, the only way to combat this tension was to support the deeper portion of the wound with sutures that dissolve over several weeks. however, scars take many months to fully develop their greatest strength. so even with the standard technique, wounds in areas of high tension still show spreading of the scar with time. the investigators believe that these wounds require an extended duration of support throughout the scar's maturation period. until recently, there did not exist a suture that could provide this long duration of support without also carrying the risk of the body rejecting it. recently, a new extremely long acting absorbable biomaterial has been fda approved for use as a suture. the investigators plan to use this suture to test the theory that alleviating stress on high tension wounds throughout the period which they gain their maximal integrity produces less scar spread and ultimately better cosmetic outcomes.


Eligibility criteria:
inclusion criteria: patients requiring excision of a lesion on chest, back, or shoulders exclusion criteria: * history of ionizing radiation * history of keloid or hypertrophic scarring * history of or current internal malignancy * history of bleeding disorder * history of collagen or elastin disorder * current use of immunosuppressive medications

Keywords: scar appearance spread
safety and tolerability of ocu-10-c-110 for injection in subjects with neovascular age-related macular degeneration

Conditions: Neovascular Age-related Macular Degeneration (nAMD)

Summary: multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the htd of ocu-10-c-110 for injection in the study eye of participants with namd

in part a, subjects will receive a single intravitreal dose in a single eye of the drug product. dose will be escalated in 3 successive cohorts, pending safety. in part b, subjects will receive 3 treatments in a single eye of drug product at 4 week intervals of the maximally tolerated dose, with an additional 4 weeks of observation for safety. .

Eligibility criteria:
inclusion criteria: 1. angiographically documented active choroidal neovascular (cnv) lesion (i.e., leakage on fluorescein angiography or subretinal, intraretinal, or sub-retinal pigment epithelium \[sub-rpe\] fluid on spectral domain optical coherence tomography \[sd-oct\]) secondary to age-related macular degeneration (amd), within the previous 10 weeks 2. subjects must have received, 7 to 14 days prior to the baseline visit, an intravitreal injection in the study eye of an anti-vascular endothelial growth factor (vegf) ocular therapeutic approved for use in the united states exclusion criteria: 1. history or current evidence of a medical condition (systemic or ophthalmic disease, metabolic dysfunction, physical examination finding or clinical laboratory finding) that may, in the opinion of the investigator, preclude the safe administration of the study medication, adherence to the scheduled study visits, or safe participation in the study or affect the results of the study (e.g., unstable or progressive cardiovascular, cerebral vascular, pulmonary, parkinson's, liver or renal disease, depression, cancer, or dementia) 2. history or evidence of the following surgeries/procedures in the study eye: 1. submacular surgery 2. vitrectomy 3. retinal detachment or retinal tear 4. incisional glaucoma surgery

Keywords: neovascular age-related macular degeneration; intravitreal
comparison of combination antibiotics eyedrop to artificial tear in hordeolum after incision and curettage

Conditions: Hordeolum

Summary: to compare the effectiveness of combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin b sulfate and gramicidin) with placebo (artificial tear) in the treatment of hordeolum after incision and curettage

hordeolum is a common eyelid disease. in case of mass, i\&c is required but role of antibiotic after i\&c is not clear. it may not need in post drainage period.

Eligibility criteria:
inclusion criteria: * at least 5-millimeters hordeolum * the onset within 7 days exclusion criteria: * previous incision and curettage of the same site within 1 month or more than 3 times * lesions in the adjacent areas suggesting of complications associated with hordeolum such as preseptal cellulitis or blepharitis * the patients with immunodeficiency, history of bleeding tendency * allergy to aminoglycoside, polymyxin b, gramicidin, xylocaine and povidone iodine

Keywords: antibiotics hordeolum
the efficacy of brief motivational interviewing for trauma patients related to alcohol or other abuse drugs.

Conditions: AODD and AODR Disorder

Summary: the purpose of this study is to determine whether the brief motivational interview will produce a significantly reduction in risk behavior than usual treatment 3 months after discharge from hospital in people who have survived a traumatism.

objectives: 1. to determine the efficacy of brief motivational interview against an usual hospital treatment (no psychological treatment) in patients who have suffered an accident under the influence of drugs (1) to reduce risk behaviors and drug consumption and (2) to increase motivation to change behavior and risk perception. 2. to investigate the mediating role of impulsive personality and decision making in the impact of brief motivational interview on reduction of risk driving. 3. to assess the economic viability of the results of brief motivational interview through a cost-utility analysis.

Eligibility criteria:
inclusion criteria: * trauma patients who have had: 1) a road crash, 2) a sport injury, 3) occupational accident. * tested positive on alcohol and/or other abuse drugs tests. exclusion criteria: * cognitive or brain-damage that prevent assessment and brief motivational interview * psychopathological disorders * residence status that prevents follow-up (residence outside of spain, homeless).

Keywords: accident prevention alcohol drinking substance-related disorders motivational interviewing adult humans intervention studies recurrence risk factors trauma centers wounds and injuries/epidemiology wounds and injuries/etiology* wounds and injuries/prevention & control*
cardiovascular risk factors on electrocardiographically and hemodynamics responses to treadmill exercise test

Conditions: Cardiovascular Diseases; Cardiovascular Abnormalities; Healthy

Summary: the goal of this observational cross-sectional study is to analyze the effect of cardiovascular risk factors in healthy and asymptomatic populations. the main questions it aims to answer are: * does the combination of the presence of different risk factors increase the risk for abnormalities appearing on electrocardiograms, such as ischemia, arrhythmia, and hemodynamics effects during and at the peak of effort of treadmill exercise test? * what are the main differences observed in the recovery period? participants will answer an anamnesis of risk factors such as sex, race, age, familiar history of coronary artery disease, overweight or obesity, smoking, stress, and physical activity practice and perform treadmill exercise test on ellestad protocol. if there a comparison groups: researchers will compare individuals with most risk factors with those without, to see the cardiovascular responses.

the main outcomes broad the effect of simples and easy doccumented cardiovascular risk factors such as sex, race, age, familiar history of coronary artery disease, overweight or obesity, smoking, stress, and physical inactivity on electrocardiogram and hemodinamics abnormalities during and after exercise treadmill exercise test.

Eligibility criteria:
inclusion criteria: * subjects that can complete the treadmill exercise test with the ellestad protocol with 6 minutes of recovery. exclusion criteria: * use of remedies for blood pressure, glycemia, cholesterol, and serum lipids; * symptomatically subjects; * electrocardiogram that are not able to be interpreted; * blood pressure in rest state ≥180 mmhg and ≥110 mmhg, for systolic and diastolic, respectively.

Keywords: treadmill exercise test asymptomatic subjects cardiovascular risk factor
placebo-controlled trial with nasonex for nasal obstruction secondary to adenoids hypertrophy in children (p04367)(terminated)

Conditions: Nasal Obstruction; Adenoids Hypertrophy; Adenoidectomy

Summary: this is a randomized, double-blind, placebo-controlled study to document the long-term effect of treatment with mometasone furoate nasal spray in moderate to severe adenoids hypertrophy as reflected by the need for removal of the adenoids within one year of the treatment regimen. subjects will be assigned treated with either mometasone furoate nasal spray or placebo for 3 months. subjects will be followed for an addition 12 months. serious aes will be followed starting first dose-till 30 days after study treatment period completion. this study was terminated - please see "p04367 - lebanon"


Eligibility criteria:
inclusion criteria: * should be between 2 and 11 years. * should have nasal obstruction for at least 3 months. * should have evidence of adenoids hypertrophy by nasopharyngoscopy, which cause \>50% obstruction of the posterior choanae. * may have concomitant allergic rhinitis, by history, \& and specific blood studies; however, the symptoms should be under control during the study period. exclusion criteria: * patients with less than 50% obstruction of the post choanae. * patients with history of recurrent epistaxis or immunodeficiency. * patients with severe septal deviation. * patients with unilateral or bilateral choanal atresia, large nasal polyps or any nasal mass. * known allergy to the drug. * presence of chronic otitis media defined as: otorreha + perforation (concomitant otitis media with effusion, or recurrent otitis media are not excluded). * cystic fibrosis \& other causes responsible for nasal obstruction. * infection (ie; sinusitis). * history of recent surgery or trauma to nose, unless all wounds have healed.
evaluation of the effect of postoperative analgesia techniques with obsqor-10

Conditions: Pain, Postoperative; Postoperative Complications

Summary: the primary objective of this study is to evaluate the effects of postoperative analgesia techniques-transversus abdominis plane (tap) block and wound infiltration-on recovery in patients undergoing elective cesarean section, using the obstetric quality of recovery-10 (obsqor-10) questionnaire. the secondary objective is to assess pain scores, analgesic consumption, and adverse effects such as nausea, vomiting, and pruritus within the first 24 hours postoperatively.

the patients will be divided into 3 groups as group t (transversus abdominis plane block), group w (wound infiltration) and group k (control). all of them will be given spinal anesthesia in sitting position.group c will receive spinal anesthesia. in group t (transversus abdominis plane block) cases, in addition to spinal anesthesia at the end of the surgery, 20 ml of 0.25% bupivacaine will be applied bilaterally between the transversus abdominis muscle and the internal oblique muscle. group wi (wound infiltration) will be administered 20 ml 0.25% bupivacaine to the wound area in addition to spinal anesthesia at the end of the surgery.numerical pain scores (nrs resting and movement), heart rate, mean arterial pressure, peripheral oxygen saturation, analgesic consumption, nausea and vomiting score, pruritus, ramsey sedation scale and other postoperative complications will be recorded at the 2nd hour, 6th hour, 12th hour and 24th hour postoperatively .obstetric quality of recovery -obsqor-10 questionnaire will be applied to the patients at the end of 24 hours.

Eligibility criteria:
inclusion criteria: * term obstetric patients aged 18-50 years who underwent elective cesarean section under spinal anesthesia and applied regional anesthesia techniques such as tap and wound infiltration. exclusion criteria: * refuse to participate in the study * patients who have undergone general anesthesia * patients requiring emergency cesarean section. * mental status disorders * known bleeding and/or coagulation disorders * infection at injection site

Keywords: cesarean section postoperative analgesia quality of recovery
blood cultures's profitability in intensive care unit

Conditions: Bacteremia

Summary: the purpose of this study is to assess the blood cultures' profitability in intensive care unit and create a validated prediction rule for extractioning in critical patients.

implementing a predictive rule blood cultures to determine the probability of positive or negative result, improving the profitability of the diagnostic test.

Eligibility criteria:
inclusion criteria: * patients who have been extracted blood culture sample exclusion criteria: * under-aged, pregnants, major burns.